Fig. 3: Major trends in disease indication and type of donor for allogeneic HCT from 1990 to 2023. | Bone Marrow Transplantation

Fig. 3: Major trends in disease indication and type of donor for allogeneic HCT from 1990 to 2023.

From: The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT

Fig. 3

a Allogeneic HCT for AML in early stage, late stage, and secondary AML from 1990 to 2023. b Change in type of donor in AML (all stages) from 1990 to 2023. c Allogeneic HCT for MDS or MDS/MPN overlap and MPN from 2004 to 2023. d Allogeneic HCT for CML in early and late stages from 1990 to 2023.

Back to article page